Primary information |
---|
sequence ID | Seq_2864 |
Peptide sequence | GLPGPPDVPDH |
CancerPDF_ID | CancerPDF_ID791, CancerPDF_ID8572, CancerPDF_ID9802, |
PMID | 19795908,23667664,21533267 |
Protein Name | Inter-alpha-trypsin inhibitor heavy chain H4,Inter-alpha-trypsin inhibitor heavy chain H4,Inter-alpha-trypsin inhibitor heavy chain H4 |
UniprotKB Entry Name | ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN |
Fluid | Plasma,Serum,Serum |
M/Z | 550.76,1099.53,550.75 |
Charge | 2,1,2 |
Mass (in Da) | NA,1101.2,NA |
fdr | NA,NA,NA |
Profiling Technique | LC-MS,MALDI-TOF,LC-MS |
Peptide Identification technique | MALDI-TOF/TOF,FT-ICR MS/MS + nano-HPLC,LC/MS/MS |
Quantification Technique | LC-MRM (multiple reaction monitoring),NA,Multiple Reaction Monitoring |
Labelled/Label Free | Labelled,Label Free,Label Free |
FDR | less than 7%,NA,1.49 |
CancerPDF_ID | CancerPDF_ID791, CancerPDF_ID8572, CancerPDF_ID9802, |
p-Value | NA,NA,NA |
Software | FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT,MASCOT |
Length | 11,11,11 |
Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma |
Database | NCBI refseq Protein Database,NA,Swissprot Database (57.4) |
Modification | NA,NA,NA |
Number of Patients | "42 normal, 28 patients","Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control |
Regulation | NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
Validation | NA,NA,MRM-based validation of 19 candidates |
Sensitivity | NA,NA,NA |
Specificity | NA,NA,NA |
Accuracy | NA,NA,NA |
Peptide Atlas | NA |
IEDB | |